A Study of ASP8302 in participants with Underactive Bladder, Trial ID 8302-CL-0201

Study summary

The study objectives of this study are to evaluate the efficacy of ASP8302 compared with placebo in participants with underactive bladder (UAB), to investigate the safety and tolerability of ASP8302 compared with placebo in participants with UAB, to investigate the pharmacokinetics of ASP8302 in participants with UAB and to support the development of the UAB - Patient Reported Outcome (PRO).

Additional Study Details

Phase

Product

ASP8302

Product

ASP8302

Placebo

Type

Interventional

Masking

Double (Participant, Investigator)

Enrollment number

135

Show Additional Study Details

Study documents

Scientific Results Summary

Available Language(s): English

Download Document(s)

Plain Language Summary

Available Language(s): English

Download Document(s)

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A Study of ASP8302 in participants with Underactive Bladder? Contact us by filling out your information to the right and we’ll respond to you.

Requestor Information [I am…]

A caregiver
A healthcare provider
A parent
A patient
A patient advocate

First name

Last Name

Country/Region

Algeria
Argentina
Armenia
Australia
Austria
Belarus
Belgium
Bosnia And Herzegovina
Brazil
Bulgaria
Canada
Chile
China
Colombia
Croatia
Czech Republic
Denmark
Dominican Republic
Egypt
Estonia
Finland
Former Serbia and Montenegro
France
Georgia
Germany
Greece
Guatemala
Hong Kong
Hungary
Iceland
India
Indonesia
Ireland
Israel
Italy
Japan
Jordan
Kazakhstan
Latvia
Lebanon
Lithuania
Macedonia
Malaysia
Mexico
Montenegro
Morocco
Netherlands
New Zealand
Norway
Panama
Peru
Philippines
Poland
Portugal
Puerto Rico
Republic of Korea
Republic of Moldova
Romania
Russian Federation
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
Spain
Sweden
Switzerland
Taiwan, Province of China
Thailand
Turkey
Ukraine
United Kingdom
United States
Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

I give my consent to the processing of my personal data mentioned above according to Astellas Privacy Notice & Cookies Policy

Locations

Completed

Site DE49001

Duisburg, Germany

Withdrawn

Site NL31004

Zwolle, Netherlands

Completed

Site JP81013

Shizuoka, Shizuoka, Japan

Completed

Site DE49002

Duisburg, Germany

Completed

Site JP81015

Sapporo, Hokkaido, Japan

Completed

Site SK42101

Nitra, Slovakia

Completed

Site NL31002

Maastricht, Netherlands

Completed

Site JP81012

Kurashiki, Okayama, Japan

Completed

Site JP81008

Obu, Aichi, Japan

Completed

Site UK44002

Bristol, United Kingdom

Completed

Site JP81001

Shimotsuga-gun, Tochigi, Japan

Completed

Site SK42103

Kosice, Slovakia

Completed

Site JP81010

Saga, Saga, Japan

Withdrawn

Site UK44003

Cambridge, United Kingdom

Completed

Site DE49004

Gronau, Germany

Completed

Site PL48004

Myslowice, Poland

Completed

Site PL48002

Szczecin, Poland

Withdrawn

Site UK44001

Sheffield, United Kingdom

Completed

Site DE49003

Moenchengladbach, Germany

Completed

Site JP81002

Kobe, Hyogo, Japan

Completed

Site JP81006

Asahikawa, Hokkaido, Japan

Completed

Site JP81009

Nagoya, Aichi, Japan

Completed

Site PL48001

Warsaw, Poland

Completed

Site JP81004

Kumamoto, Kumamoto, Japan

Completed

Site PL48003

Piaseczno, Poland

Completed

Site JP81011

Osakasayama, Osaka, Japan

Completed

Site NL31003

Eindhoven, Netherlands

Completed

Site JP81005

Sapporo, Hokkaido, Japan

Completed

Site SK42102

Trencin, Slovakia

Completed

Site JP81003

Fukuoka, Fukuoka, Japan

Completed

Site JP81007

Yoshida-gun, Fukui, Japan

Completed

Site NL31001

Rotterdam, Netherlands

Trial info

Follow Trial

Age

18+ years

Condition

Underactive Bladder

Sex

Female & Male

Trial Dates

Nov 2018 - Apr 2020

Share with

Additional Study Details

Inclusion Criteria

At visit 1:

Subject is diagnosed with UAB, defined as a bothersome chronic incomplete bladder emptying:
- clinical condition is present for ≥ 6 months before screening, and
- subject has a PVR ≥ 75 mL (measured by ultrasound after uroflowmetry; V1-PVRUS1).
Subject on clean intermittent catheterization (CIC) should have been on CIC for at least 1 month and should be able to void spontaneously and not be completely dependent on CIC.
Female subject must either:
- Be of non-childbearing potential; post-menopausal (defined as at least 1 year without any menses for which there is no other obvious pathological or physiological cause) prior to screening, or documented surgically sterile (e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy).
- Or, if of childbearing potential; agrees not to try to become pregnant during the study and for 28 days after the final study drug administration, agrees to have a serum pregnancy test on all visits, have a negative serum pregnancy test at the screening visit, and agrees to consistently use 1 form of highly effective birth control starting at screening and throughout the study period and for 28 days after the final study drug administration.
Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 28 days after the final study drug administration.
Female subject must not donate ova starting at screening and throughout the study period, and for 28 days after the final study drug administration.
A sexually active male subject with female partner(s) of childbearing potential is eligible if he agrees to use a male condom starting at screening and continue throughout study treatment and for 90 days after the final study drug administration. If the male subject has not had a vasectomy or is not sterile, his female partner(s) is utilizing 1 form of highly effective birth control starting at screening and will continue throughout study treatment and for 90 days after the male subject receives the final study drug administration.
Male subject must not donate sperm starting at screening and throughout the study period and for 90 days after the final study drug administration.
Male subject with a pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 28 days after the final study drug administration.
Subject agrees not to participate in another interventional study while participating in this study.

At visit 2:

Subject has a PVR ≥ 100 mL (measured by catheterization, i.e., PVRC2).
Subject has a VVST ≥ 50 mL and a bladder voiding efficiency ((BVE) (V2_BVE)) ≥ 10%. The VVST and V2_PVRC2 will be used to calculate V2_BVE = [VVST/(V2_PVRC2 + VVST)] times 100.

Exclusion Criteria

At visit 1:

Related to lower urinary tract:

Subject has significant BOO:
- Subject has clinically significant urethral stricture (e.g., requiring surgery).
- Female subject has uterus prolapse ≥ Grade 2 Shaw’s system (up to or outside the introitus), moderate or severe cystocele (reaches or protrudes outside the introitus).
- Male subject has a bladder outlet obstruction index (BOOI) ≥ 40 cm H2O on pressure flow study (PFS) (either performed on screening or within 12 months of the screening visit), or –if PFS is not available–a prostate volume (PV) of > 40 mL (Europe) > 30 mL (Japan) on ultrasound (either performed on screening or within 6 months of the screening visit). Note: if PFS is available and PV is above the cut-off level, the subject is not to be excluded

if bladder outlet obstruction index (BOOI) is < 40.

Other condition that constitutes significant BOO.
Subject is known to have urgency urinary incontinence that is clinically significant.
Subject is known to have 1 or more bladder diverticuli that is/are clinically significant.
Subject is known to have vesico-ureteral/renal reflux that is clinically significant.
Subject has a urinary catheter in situ (including suprapubic catheters).
Subject is known to have 1 of the following conditions as a primary cause for subject's UAB, or a condition that could potentially influence treatment outcome:
- Neurological lesion or condition, including cerebrovascular accident, spinal lumbar disc hernia, spinal cord injury, multiple sclerosis, Parkinson’s disease, Guillain–Barré syndrome, pudendal, hypogastric or pelvic nerve lesion. Diabetes mellitus is allowed if controlled with or without medical treatment (e.g., HbA1C < 7%).
- Increased pelvic floor muscle activity during voiding (e.g., dyssynergic striated sphincteric activity/striated sphincteric activity during voiding, Fowler syndrome and pelvic floor muscle spasm).
- Previous bladder surgery (e.g., bladder augmentation or reduction surgery, latissimus dorsi detrusor myoplasty). Prior Benign Prostatic Obstruction surgery or pelvic organ prolapse surgery is allowed if performed more than 6 months prior to screening.
- Previous implant surgery for incontinence still in situ (e.g., tape, sling or artificial sphincter)
- Significant active urological pain syndrome.
- Previous pelvic radiation therapy.
Dependence on use of a manual assistance method intended to improve bladder emptying (e.g., Credé's maneuver or suprapubic tapping).

Related to (previous or current) treatment and/or study drug:

Subject is receiving 1 or more of the following non-medication therapies:
- Electrostimulation therapy, e.g., neurostimulation/modulation or sacral nerve stimulation in the past 3 months.
- Intravesical or injection based treatment (e.g., botulinum toxin injections in urethra or bladder in the past 12 months).
- An ongoing bladder training program and/or pelvic floor muscle exercises, which started within 6 weeks prior to visit 1.
- Muscle-derived stem cell injection in the bladder or urethra or bladder

transplantation at any time prior to screening.

Subject is using prohibited medications or subject is using restricted medications under conditions different to those specified in the concomitant medication section.
Subject has a known or suspected hypersensitivity to ASP8302 or any of the inactive ingredients.

Related to concomitant conditions:

(Please note that these exclusion criteria do not require specific diagnostic evaluation during the screening visit, unless the subject presents with signs and symptoms suggesting the presence of this condition that were not present earlier.)

Subject is known to have inflammatory bowel disease or clinically significant diarrhea.
Subject is known to be immunocompromised due to conditions such as human immunodeficiency virus/acquired immune deficiency syndrome or hepatitis C.
Subject has been diagnosed with clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to visit 1, such as myocardial infarction, uncontrolled angina/coronary artery disease, significant ventricular arrhythmias and heart failure (New York Heart Association class III/IV).
Subject has been diagnosed with clinically significant asthma, chronic bronchitis and/or chronic obstructive pulmonary disease.
Subject is known to have a mean Fridericia corrected QT interval (QTcF) > 430 ms for males or > 450 ms for females, a pre-existing long QT syndrome or hypokalemia.
Subject has a clinically significant abnormal 12-lead ECG.
Subject has current or previous malignant disease of the pelvis. Subjects with a history of (non-pelvic) cancer are considered eligible if the subject has undergone therapy and the subject has been considered disease free for at least 5 years. Subject with completely excised basal cell carcinoma or squamous cell carcinoma of the skin and completely excised cervical cancer in situ are also considered eligible.
Subject is known to have moderate to severe hepatic impairment (i.e., Child-Pugh class B or C).
Subject is known to have severe renal impairment defined as estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m^2.
Subject is known to have current or history of alcohol and/or drug abuse within the last 24 months prior to screening.
Subject has clinical signs and symptoms of a urinary tract infection (UTI), which is combined with a result of urine test (e.g., positive urine culture containing > 100,000 cfu/mL in midstream urine). If a UTI is confirmed in the visit 1 sample, the run-in period should be stopped. After successful treatment of the UTI, the subject can be rescreened and if eligible enroll in the study. If the subject has asymptomatic bacteriuria (i.e., a positive urine culture without clinical signs and symptoms of a UTI), the subject should not be excluded.
Subject has any of the following abnormal liver or kidney function parameters (as assessed in visit 1 sample):
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or bilirubin increased to > 1.5 times the upper limit of normal (ULN).
- Gamma glutamyltransferase (γ-GT) increased to > 3 times the ULN.
- eGFR < 45 mL/min/1.73 m^2 based on the Modification of Diet in Renal Disease formula.

General:

Subject has received investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.
Subject is known to have any condition, which makes the subject unsuitable for study participation.

At visit 2:

Subject meets any of the exclusion criteria of visit 1.
Subject has severe overactive bladder (OAB), i.e., experienced 3 or more episodes of urgency (Patient Perception of Intensity of Urgency Scale (PPIUS) grade 3 or 4), during the 3-day micturition diary period prior to visit 2.

Frequently Asked Questions

Are clinical trials only for people with advanced cancer?

While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

Will I have to stop my current treatment to participate in a clinical trial?

Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

Should I be worried about getting a placebo?

In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

Do I need a referral from my doctor to take part in a study?

Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

Explore More

A Study of ASP8302 in participants with Underactive Bladder

Study summary

Additional Study Details

Study documents

Get more information

Locations

Frequently Asked Questions

Explore More

What are clinical trials?

Why are Clinical Trials Important?

Why Participate in a Clinical Trial?